Looking Back to Leap Forward: Our 2025 Strategic Debrief
The end-of-year period is often synonymous with taking stock, but for Research & Development teams, it is above all a springboard for 2026 strategic planning.
It is the ideal opportunity to optimize R&D investments by asking one central question : In 2026, how can we guarantee that every new formula perfectly meets consumer expectations for performance and visible results ?
Resolution No. 1 : Prioritizing Objectivity
In 2026, market expectations are clear: consumers no longer want supplements based on ‘faith’; they want guaranteed results.
This demand is well-founded: according to the DGCCRF (2025), simply listing an ingredient does not guarantee its efficacy, which frequently leads to non-compliance due to unsubstantiated claims. Furthermore, dissatisfaction is global, with 81% of consumers demanding more scientific evidence for beauty claims (Source: Mintel Global Consumer, 2023).
For professionals, this translates into a single resolution: prioritizing objectivity. By mastering dosage, bioavailability, and clinical evidence, innovation becomes a lever for sustainable growth.
NOVASTYNE®: Your Guarantee of Efficacy for 2026
At NOVACTIVA, we design solutions engineered for tomorrow’s standards. Our range of patented bioactive peptide complexes (NOVASTYNE® GLOW and FLEX) has been developed to provide a concrete response to the market’s new demands for precision.
Our commitment for 2026
⭐ Validated Efficacy: Clinical and in vitro results that speak for themselves (request the brochure on our contact page)
⭐ Safety and Traceability: A natural manufacturing process, certified ‘Origine France Garantie‘ (OFG) and with Non-Novel Food status.
The new year is the perfect time to choose measured performance and give your future launches the power of scientific proof.
The entire NOVACTIVA team sends you their best wishes for the new year. We are now at your disposal to plan the integration of NOVASTYNE® into your 2026 formulations.
